Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PROKR1 | Q8TCW9 | 12/20 | 0.46 |
| ▸ | MAP3K12 | Q12852 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17898209 | 0.82 | PROKR1 (0.46) | PROKR1MAP3K12 | |
| SCHEMBL17898200 | 0.77 | PROKR1 (0.45) | PROKR1MAP3K12 | |
| SCHEMBL20746672 | 0.71 | PDE2A (0.47) | KMT2A | |
| SCHEMBL14444260 | 0.67 | ALDH1A1 (0.63) | KMT2AHPGDUSP2ALDH1A1 | |
| SCHEMBL14444256 | 0.66 | ALDH1A1 (0.65) | KMT2AHPGDUSP2ALDH1A1 | |
| SCHEMBL28769750 | 0.64 | PROKR1 (0.52) | PROKR1MAP3K12 | |
| SCHEMBL3587216 | 0.63 | GRM5 (0.55) | PROKR1KMT2AALDH1A1 | |
| SCHEMBL3587220 | 0.63 | GRM5 (0.55) | PROKR1KMT2AALDH1A1 | |
| SCHEMBL30796556 | 0.63 | GRM5 (0.55) | PROKR1KMT2AALDH1A1 | |
| SCHEMBL16446410 | 0.63 | PROKR1 (0.79) | PROKR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562883-B2 | Heterocycles capable of modulating T-cell responses, and methods of using same | NOGRA PHARMA LIMITED (IE) | 2020-02-18 | — | — | US | disclosed |
| US-10208017-B2 | Heterocycles capable of modulating T-cell responses, and methods of using same | NOGRA PHARMA LIMITED (IE) | 2019-02-19 | — | — | US | disclosed |
| US-20160194303-A1 | HETEROCYCLES CAPABLE OF MODULATING T-CELL RESPONSES, AND METHODS OF USING SAME | NOGRA PHARMA LIMITED (IE) | 2016-07-07 | — | — | US | disclosed |
| US-20160194303-A1 | HETEROCYCLES CAPABLE OF MODULATING T-CELL RESPONSES, AND METHODS OF USING SAME | NOGRA PHARMA LIMITED (IE) | 2016-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194303-A1 | HETEROCYCLES CAPABLE OF MODULATING T-CELL RESPONSES, AND METHODS OF USING SAME | ICOS, NFATC1, CD74 | PROKR1 2669/4885MAP3K12 1704/4885KMT2A 2664/4885 |
| US-10562883-B2 | Heterocycles capable of modulating T-cell responses, and methods of using same | ICOS, NFATC1, CD74 | PROKR1 2669/4885MAP3K12 1704/4885KMT2A 2664/4885 |
| US-10208017-B2 | Heterocycles capable of modulating T-cell responses, and methods of using same | ICOS, NFATC1, CD74 | PROKR1 2669/4885MAP3K12 1704/4885KMT2A 2664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.